Oxford’s new MSc in Nanotechnology for Medicine and Health Care builds on the world-leading research in nanomedicine at the University’s Institute of Biomedical Engineering and other departments in the Mathematical, Physical and Life Sciences (MPLS) Division and Medical Sciences Division. This advanced modular course is delivered by leading scientists and experts in this rapidly developing field and has been specifically designed for those who would value a part-time modular learning structure, for example those in full-time employment, both in the UK and overseas.
The MSc is designed to be completed part-time, normally over a two- to three-year period, and so provides a path to career development that is flexible and recognised within academia and industry. The programme comprises three online modules exploring the fundamentals of science and materials characterisation at the nanoscale, three intensive five-day face-to-face modules describing the clinical and commercial application of such science, and a piece of original lab-based research leading to the submission of a dissertation. This modular structure provides an adaptable approach to learning, and each module may also be taken as an individual short course.
There are opportunities to access and learn about cutting-edge research and current practice in a wide range of nanotechnology and healthcare topics from experts with experience of taking nanotechnologies from basic concept through clinical validation to market realisation. The tutor-led approach lends cohesion to the modular experience which is tailored for busy people in full-time employment who wish to minimise time away from the workplace to study.
If your application is completed by this January deadline and you fulfil the eligibility criteria, you will be automatically considered for a graduate scholarship. For full details please see: http://www.ox.ac.uk/admissions/graduate/fees-and-funding/graduate-scholarships.
Nanotechnology is the production and application of devices and systems at the nanometre scale, which is of the order of one billionth of a metre. Developments in this area of technology are now coming to fruition, and increasingly impacting on our daily lives. In particular, nanotechnology is becoming a crucial driving force behind innovation in medicine and healthcare, with a range of advances including nanoscale therapeutics, biosensors, implantable devices and imaging systems. However, the pace with which this revolution is occurring has left even some of its leading practitioners lacking in aspects of the key fundamental knowledge or the information required to navigate the regulatory and clinical pathway to achieve market realisation.
The University of Oxford's MSc in Nanotechnology for Medicine and Health Care offers a detailed and cutting-edge education in this subject and builds on the successful Postgraduate Certificate in Nanotechnology, which was launched in 2006. The course is taken part-time as a mixture of online and face-to-face modules, meaning it can fit around the demands of those working full-time and can be studied by international students without the requirement to relocate. The course uses a blend of individual study of learning materials, together with group work during live online tutorials, conventional lectures and discussions and also requires the student to submit a dissertation reporting an original piece of nanomedicine-based research. The group sessions with tutors are particularly valuable because they offer highly focused learning and assessment opportunities.
The MSc in Nanotechnology for Medicine and Health Care is a part-time course consisting of six modules and a research project and associated dissertation. The programme is normally completed in two to three years. Students are full members of the University of Oxford and are matriculated as members of an Oxford college.
The modules in this programme can also be taken as individual short courses. It is possible to transfer credit from up to three previously completed modules into the MSc programme, if the time elapsed between commencement of the accredited module(s) and registration on the MSc is not more than two years.
The course comprises:
- three online modules giving a thorough introduction to the fundamental science of nanotechnology and the behaviour and characterisation of nanoscale materials;
- three five-day modules taught face-to-face in Oxford explaining the scientific, regulatory, clinical and commercial aspects of the application of nanotechnology to medicine and healthcare
- an original research project of approximately 18 weeks to be written up as a dissertation
The course has a dedicated Course Director, Associate Director and administration team accustomed to supporting students undertaking distance learning and face-to-face courses. Students have access to staff at the University of Oxford’s Begbroke Science Park and Institute of Biomedical Engineering, particularly the Course Director, Professor Robert Carlisle and the Associate Course Director, Dr Christiane Norenberg.
Throughout the course, students can use the University of Oxford’s excellent electronic library resources to enable them to complete the assignment tasks.
- Module 1: The Wider Context of Nanotechnology (online)
- Module 2: The Fundamental Science of Nanotechnology (online)
- Module 3: Fundamental Characterisation for Nanotechnology (online with two-day component in Oxford)
- Module 4: Introduction to Bionanotechnology (in Oxford)
- Module 5: Nanomedicine – Science and Applications (in Oxford)
- Module 6: Clinical Translation and Commercialisation of Nanomedicine (in Oxford)
To complete the MSc, students need to attend the six modules and complete the assessed written assignments for each module, and complete a research project with dissertation on a topic chosen in consultation with a supervisor and the Course Director.
This is a part-time, modular course leading to a postgraduate qualification at the University of Oxford. The course is designed for students wishing to study part-time. It will appeal to those working in the commercial, research or healthcare sectors who use or develop nanotechnology in their work. Applications are welcome from biomedical engineers, materials scientists, biotech-entrepreneurs, medical practitioners, chemists, pharmacists, electrical engineers, project managers in related industries, patent agents, legislators, as well as those involved in commercial or academic research in this area of science.
Find out how to apply here - http://www.ox.ac.uk/admissions/graduate/applying-to-oxford
The Department of Oncology and the Department for Continuing Education’s CPD Centre offer a part-time MSc in Experimental and Translational Therapeutics that brings together some of Oxford's leading clinicians and scientists to deliver an advanced modular programme designed for those in full-time employment, both in the UK and overseas.
The Programme draws on the world-class research and teaching in experimental therapeutics at Oxford University and offers a unique opportunity to gain an understanding of the principles that underpin clinical research and to translate this into good clinical and research practice.
Visit the website https://www.conted.ox.ac.uk/about/msc-in-experimental-therapeutics
If your application is completed by this January deadline and you fulfil the eligibility criteria, you will be automatically considered for a graduate scholarship. For details see: http://www.ox.ac.uk/admissions/graduate/fees-and-funding/graduate-scholarships.
The MSc in Experimental and Translational Therapeutics is a part-time course consisting of six modules and a research project and dissertation. The programme is normally completed in two to three years. Students are full members of the University of Oxford and are matriculated as members of an Oxford college.
The modules in this programme can also be taken as individual short courses. It is possible to transfer credit from up to three previously completed modules into the MSc programme, if the time elapsed between commencement of the accredited module(s) and registration for the MSc is not more than two years.
- The Structure of Clinical Trials and Experimental Therapeutics
- Drug Development, Pharmacokinetics and Imaging
- Pharmacodynamics, Biomarkers and Personalised Therapy
- Adverse Drug Reactions, Drug Interactions, and Pharmacovigilance
- How to do Research on Therapeutic Interventions: Protocol Preparation
- Biological Therapeutics
The aim of the MSc programme is to provide students with the necessary training and practical experience to enable them to understand the principles that underpin clinical research, and to enable them to translate that understanding into good clinical and research practice.
By the end of the MSc programme, students should understand the following core principles:
- Development, marketing and regulations of drugs
- Pharmaceutical factors that affect drug therapy
- Pharmacokinetics, pharmacogenetics and pharmacodynamics
- Adverse drug reactions, drug interactions, and pharmacovigilance
- Designing phase I, II and III clinical trials for a range of novel therapeutic interventions (and imaging agents).
- Application of statistics to medicine
- Laboratory assays used to support trial end-points
- Use of non-invasive imaging in drug development
- Application of analytical techniques
By the end of the programme, students should be equipped to:
- demonstrate a knowledge of the principles, methods and techniques for solving clinical research problems and translate this into good clinical and research practice
- apply skills gained in techniques and practical experience from across the medical and biological sciences
- develop skills in managing research-based work in experimental therapeutics
- carry out an extended research project involving a literature review, problem specification and analysis in experimental therapeutics and write a short dissertation
Guidance from the UK Royal College of Physician's Faculty of Pharmaceutical Medicine
The Faculty have confirmed that if enrolled for Pharmaceutical Medicine Specialty Training (PMST), trainees may be able to use knowledge provided by Experimental Therapeutics modules to cover aspects of a module of the PMST curriculum. Trainees are advised to discuss this with their Educational Supervisor.
Experimental Therapeutics modules may also be used to provide those pursuing the Faculty's Diploma in Pharmaceutical Medicine (DPM) with the necessary knowledge required to cover the Diploma syllabus. Applicants for the DPM exam are advised to read the DPM syllabus and rules and regulations.
Members of the Faculty of Pharmaceutical Medicine who are registered in the Faculty's CPD scheme can count participation in Experimental Therapeutics modules towards their CPD record. Non-members may wish to obtain further advice about CPD credit from their Royal College or Faculty.
To complete the MSc, students need to:
Attend the six modules and complete an assessed written assignment for each module.
Complete a dissertation on a topic chosen in consultation with a supervisor and the Course Director.
The dissertation is founded on a research project that builds on material studied in the taught modules. The dissertation should normally not exceed 15,000 words.
The project will normally be supervised by an academic supervisor from the University of Oxford, and an employer-based mentor.
The following are topics of dissertations completed by previous students on the course:
- The outcomes of non-surgical management of tubal pregnancy; a 6 month study of the South East London population
- Analysis of the predictive and prognostic factors of outcome in a cohort of patients prospectively treated with perioperative chemotherapy for adenocarcinoma of the stomach or of the gastroesophageal junction
- Evolution of mineral and bone disorder in early Chronic Kidney Disease (CKD): the role of FGF23 and vitamin D
- Survey of patients' knowledge and perception of the adverse drug reporting scheme (yellow cards) in primary care
- The predictive role of ERCC1 status in oxaliplatin based Neoadjuvant for metastatic colorectal cancer (CRC) to the liver
- Endothelial Pathophysiology in Dengue - Dextran studies during acute infection
- Literature review of the use of thalidomide in cancer
- An investigation into the phenotypical and functional characteristics of mesenchymal stem cells for clinical application
- Identification of genetic variants that cause capecitabine and bevacizumab toxicity
- Bridging the evidence gap in geriatric medicines via modelling and simulations
The class-based modules will include a period of preparatory study, a week of intensive face-to-face lectures and tutorials, followed by a period for assignment work. Attendance at modules will be a requirement for study. Some non-classroom activities will be provided at laboratory facilities elsewhere in the University. The course will include taught material on research skills. A virtual learning environment (VLE) will provide between-module support.
The taught modules will include group work, discussions, guest lectures, and interaction and feedback with tutors and lecturers. Practical work aims to develop the students' knowledge and understanding of the subject.
Find out how to apply here - http://www.ox.ac.uk/admissions/graduate/applying-to-oxford